Skip to main content

Table 1 Key baseline patient demographics and characteristics

From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Characteristic

Overall (N = 130)a

Patients with best response of SD (n = 32)

Age, median (range), y

61 (20–83)

61.5 (24–79)

ECOG performance statusb

 0

46 (35)

10 (31)

 1

66 (51)

17 (53)

 2

17 (13)

5 (16)

International Prognostic Index, n (%)

 <2

31 (24)

7 (22)

 ≥2

99 (76)

25 (78)

PTCL subtype based on central review, n (%)

 PTCL-NOS

69 (53)

16 (50)

 AITL

27 (21)

8 (25)

 ALK-1-negative ALCL

21 (16)

5 (16)

 Other

13 (10)c

3 (9)d

Stage III/IV at diagnosis, n (%)

91 (70)

20 (63)

Number of prior therapies, n (%)

 1

38 (29)

13 (41)

 2

44 (34)

11 (34)

 3

19 (15)

3 (9)

 4

15 (12)

4 (13)

 >4

14 (11)

1 (3)

Type of prior therapy, n (%)

 Chemotherapy

129 (99)

31 (97)

 Monoclonal antibody therapy

20 (15)

3 (9)

 Other immunotherapy

14 (11)

1 (3)

 Radiation

31 (24)

8 (25)

 ASCT

21 (16)

3 (9)

Refractory to most recent therapy, n (%)

49 (38)

8 (25)

  1. ASCT autologous stem cell transplant
  2. a PTCL histologically confirmed by central pathology review
  3. b One patient in the overall population had missing ECOG performance status at baseline
  4. cIncludes enteropathy-associated TCL (6), subcutaneous panniculitis-type TCL (3), ALK-1-positive ALCL (1), cutaneous γδ TCL (1), extranodal NK/TCL nasal type (1), and transformed mycosis fungoides (1)
  5. dIncludes enteropathy-type TCL (1), subcutaneous panniculitis-like TCL (1), and cutaneous γδ TCL (1)